Resveratrol in the prevention of colorectal polyps

Not Applicable

Completed

• Conditions: high risk/familial risk of colorectal cancer; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Cancer - Bowel - Back passage (rectum) or large bowel (colon)

• Registration Number: ACTRN12611000560998
• Lead Sponsor: Melbourne Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-06-01
• Study Completion: 2015-01-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

HNPCC carriers

Exclusion Criteria

pregnancy, co-morbidities

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
inflammation biomarkers (eg IL-6, CRP) , through rectal biopsies[at six weeks on conclusion of intervention];expression of genes involved in normal structure and function of colorectal epithelium altered early in colorectal carcinogenesis, through rectal biopsies (Ki67 and TGF markers, apotosis markers Bax, Bc12 and bak, APC, beta-catenin and mismatch repair proteins)[at six weeks on conclusion of intervention];colorectal epithelial crypt cell cycle events, through rectal biopsies[at six weeks on conclusion of intervention]

Secondary Outcome Measures

Name	Time	Method
local growth factor biomarkers, through rectal biopsies[at six weeks on conclusion of intervention]